This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Drug Stocks Rally: Consider These Profitable Stocks as Pharmaceutical Deals Rise

Mary Lynn Cesar, Kapitall: Will Actavis's announced $25 billion purchase of Forest Labs increase the appeal of drug stocks?

Leading generic drug company Actavis (ACT) agreed to buy branded drug maker Forest Laboratories (FRX) for $25 billion on Tuesday morning. The agreement states that Actavis will acquire Forest Labs for $89.48 per share in cash and stock. Following the announcement, MarketWatch reports that shares of Forest Labs and Actavis surged by 30% and 7.9%, respectively, in early morning trading.

[Read more from Kapitall: Will Offshore Tax Havens Face More Scrutiny in 2014?]

The Actavis-Forest Labs deal is the latest consolidation in an industry increasingly beseiged by bids and acquisitions. Last year Actavis rejected multi-billion dollar offers from fellow generic drug makers Mylan Inc. (MYL) and Valeant Pharmaceuticals (VRX), opting to purchase branded drug manufacturer Warner Chilcott for $5 billion instead. According to Bloomberg, roughly $110 billion in drug and biotechnology deals took place between February 2013 and February 2014.

More deals are expected as Valeant CEO Mike Pearson seeks to build his firm into one of the largest drug companies in the world with a market cap exceeding $150 billion by the end of 2016. Just this month Valeant acquired privately held PreCision Dermatology for $475 million. And Businessweek writes that Pearson told Goldman Sachs conference attendees in January that later this year Valeant plans a “significant” deal similar to its earlier $8.7 billion acquisition of Bausch & Lomb.

Investing Ideas

The recent activity in these drug stocks inspired us to look for other investment opportunities in this sector. To begin, we constructed a universe comprised of drug stocks belonging to the "drugs manufacturers – generic" and "drug manufacturers — other" industries. We selected those specific industries instead of using all drug-related segments because Actavis belongs to the former while Forest Labs is part of the latter.

We then screened for increasingly profitable stocks as indicated by rising gross profit margins year-over-year for the last three years. Gross margin is the percentage of profit a company makes for each dollar it generates in sales, after deducting production expenses. Examples of these expenses include operating costs, payroll, and taxes. The formula is:

Gross Margin = Gross Profit / Revenue

The higher the percentage, the greater the gross profits a company takes from its revenue. When a company has rising gross margins, it indicates that the firm is in control of its costs.

Next, we screened for stocks that are rallying above their 20-day, 50-day, and 200-day moving averages (MA). This indicates that these stocks have strong upward momentum.

We were left with four drug stocks on our list.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,162.99 +121.45 0.67%
S&P 500 2,123.48 +19.28 0.92%
NASDAQ 5,106.5930 +73.8420 1.47%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs